These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
424 related items for PubMed ID: 23077849
1. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children. Pancharoen C, Chotpitayasunondh T, Chuenkitmongkol S, Ortiz E. Southeast Asian J Trop Med Public Health; 2012 May; 43(3):687-98. PubMed ID: 23077849 [Abstract] [Full Text] [Related]
7. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Heininger U, DTP-HBV-IPV-059 Study Group, DTP-HBV-IPV-096 Study Group, Sänger R, Jacquet JM, Schuerman L. Vaccine; 2007 Jan 22; 25(6):1055-63. PubMed ID: 17049692 [Abstract] [Full Text] [Related]
8. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America. López P, Arguedas Mohs A, Abdelnour Vásquez A, Consuelo-Miranda M, Feroldi E, Noriega F, Jordanov E, B Chir S, Zambrano B. Pediatr Infect Dis J; 2017 Nov 22; 36(11):e272-e282. PubMed ID: 28719500 [Abstract] [Full Text] [Related]
9. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine. Madhi SA, Cutland C, Jones S, Groome M, Ortiz E. S Afr Med J; 2011 Nov 28; 101(12):879-83. PubMed ID: 22273029 [Abstract] [Full Text] [Related]
11. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children. Halperin SA, Langley JM, Hesley TM, Zappacosta PS, Radley D, Smith B, Hoffenbach A, Boslego J, Silber JL. Hum Vaccin; 2005 Nov 28; 1(6):245-50. PubMed ID: 17012871 [Abstract] [Full Text] [Related]
12. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, haemophilus influenzae type B vaccine among Thai children at 18-19 months of age. Chotpitayasunondh T, Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E. Southeast Asian J Trop Med Public Health; 2012 Mar 28; 43(2):442-54. PubMed ID: 23082595 [Abstract] [Full Text] [Related]
13. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez-Campderá JA, Navarro ML, Merino JM, Martín-Ancel A, Roca J, García-del-Río M, Jurado A, Díez-Delgado FJ, Omeñaca F, García-Sicilia J, Boceta R, García-Corbeira P, Jacquet JM, Collard A, Schuerman L, Spanish DTaP-HBV-IPV-097 Study Group. Pediatr Infect Dis J; 2006 Aug 28; 25(8):713-20. PubMed ID: 16874171 [Abstract] [Full Text] [Related]
14. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants. Lin TY, Wang YH, Chang LY, Huang YC, Kao HT, Lin PY, Lu HK, Chavand P, Ortiz E. Int J Infect Dis; 2007 Mar 28; 11(2):129-36. PubMed ID: 16762579 [Abstract] [Full Text] [Related]
16. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Kosalaraksa P, Thisyakorn U, Benjaponpitak S, Chokephaibulkit K, Santos-Lima E. Int J Infect Dis; 2011 Apr 28; 15(4):e249-56. PubMed ID: 21334243 [Abstract] [Full Text] [Related]
17. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China. Li RC, Li FX, Li YP, Hou QM, Li CG, Li YN, Chen FS, Hu XZ, Su WB, Zhang SM, Fang HH, Ye Q, Zeng TD, Liu TX, Li XB, Huang YN, Deng ML, Zhang YP, Ortiz E. Vaccine; 2011 Nov 21; 29(50):9337-44. PubMed ID: 22001281 [Abstract] [Full Text] [Related]
18. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants. Olivier C, Belohradsky BH, Stojanov S, Bonnet E, Petersen G, Liese JG. Vaccine; 2008 Jun 13; 26(25):3142-52. PubMed ID: 18502545 [Abstract] [Full Text] [Related]
19. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B conjugate combination vaccine (Pentaxim) with hepatitis B vaccine. Dutta AK, Verghese VP, Pemde HK, Mathew LG, Ortiz E. Indian Pediatr; 2009 Nov 13; 46(11):975-82. PubMed ID: 19955579 [Abstract] [Full Text] [Related]
20. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States. Klein NP, Abu-Elyazeed R, Cheuvart B, Janssens W, Mesaros N. Hum Vaccin Immunother; 2019 Nov 13; 15(4):809-821. PubMed ID: 30444673 [Abstract] [Full Text] [Related] Page: [Next] [New Search]